Quintiles talks R&D spend and outsourcing trend in Second Public Offering

By Dan Stanton

- Last updated on GMT

Related tags Pharmacology

Quintiles will not receive proceeds from SPO but predicts a rosy future for CROs
Quintiles will not receive proceeds from SPO but predicts a rosy future for CROs
Nearly 40% of the $51bn spent on clinical development last year was outsourced according to Quintiles, which has predicted continued growth for the CRO industry in documents outlining its second public offering.

Ten months after it went public​, the world’s largest contract research organisation (CRO) announced this morning that certain stockholders plan to sell 15 million shares in a second public offering.

According to a prospectus filed with the SEC​, Quintiles will not receive any proceeds from the sale of the shares, which are being divested by a diverse group of investors [page 46] including former CEO Dennis Gillings.

The CRO also used the document to outline its view of the contract research industry, and forecast that demand for third-party services will increase.

“R&D spending was approximately $137bn [€99bn] in 2013 and will grow to approximately $145 billion in 2016,”​ the firm said, adding drug development accounted for around 68% - $93bn – of the total expenditure.

This was broken down further by the firm, with spending on clinical development – rather than preclinical – reaching $51bn.

“We estimate that the potential market for Product Development’s services will experience a CAGR of 6%-8% from 2013 through 2016 as a result of increased research and development spending by biopharmaceutical companies and the increased outsourcing of this spending as compared to 2012.”

R&D spend

Efforts to replenish revenue from the ‘patent cliff’ has led to this surge in R&D spend, as has an increase in access to capital by small and mid-tier biotech firms.

Furthermore, recent increases in pharmaceutical approvals by regulatory authorities have encouraged further spend, the report said, with 2013 seeing 4,060 drugs in the Phase I-III pipeline (a 19% since 2008) and 27 NME (new molecular entities) approvals by the United States Food and Drug Administration.

Outsourcing Trend

Of total development clinical spend, Quintiles estimates around $19bn (37%) of this was outsourced last year, a figure expected to grow to $23bn by 2016.

The need for firms to “maximize productivity and lower costs in their product development and commercial operations” ​will drive this, Quintiles predicts, as will the emergence of more complex therapeutic areas, such as biologics, genetically targeted therapies, and stem cell therapies.

Increased regulatory oversight will also encourage this outsourcing trend as will a continued global outlook. “Understanding the epidemiological and physiological differences in different ethnic populations and being able to conduct trials locally in certain geographies will be important to pharmaceutical product growth strategies, both for multinational and local/regional biopharmaceutical companies.”

The CRO also predicted the industry’s move towards long-term strategic alliances would continue: “Biopharmaceutical companies have historically preferred, and will continue to prefer, financially sound, global service providers with broad therapeutic and functional expertise such as our company when selecting strategic providers.”

Quintiles inked a five-year exclusive deal with Merck Serono​ just days after its IPO was finalised.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more